Welcome to our dedicated page for Aim Immunotech SEC filings (Ticker: AIMI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The AIM ImmunoTech Inc. (AIMI/AIM) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a smaller reporting biotechnology issuer focused on immuno-pharma therapeutics. AIM ImmunoTech files annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, proxy statements on Schedule 14A and other forms that document its financial condition, governance decisions and material events.
For investors tracking AIM ImmunoTech’s development-stage biotechnology business, the company’s periodic reports are central. The Form 10-K and Form 10-Q filings describe its status as a smaller reporting company, summarize its focus on therapeutics for cancers, immune disorders and viral diseases, and provide financial statements that reflect revenues and net losses consistent with a research-focused enterprise. A Form 12b-25 (Notification of Late Filing) for the quarter ended September 30, 2025 explains delays in completing the required review, outlines the expectation to file within the permitted extension period and describes anticipated changes in revenues, net loss and loss per share compared to prior-year periods.
AIM ImmunoTech also uses Form 8-K to report material events. Examples include furnishing a corporate presentation under Regulation FD, disclosing NYSE American notices of noncompliance with minimum stockholders’ equity requirements and the acceptance of a plan to regain compliance, and filing its Certificate of Incorporation as amended and restated as an exhibit. These current reports help investors understand exchange listing issues, governance documents and other significant developments beyond routine financial reporting.
Proxy statements on Schedule 14A, such as the definitive proxy for the 2025 Annual Meeting of Stockholders, provide detail on board elections, advisory votes on executive compensation, auditor ratification and the company’s use of scaled disclosure obligations as a smaller reporting company. Voting results for proposals, reported via Form 8-K, show how stockholders have voted on directors, compensation matters and the frequency of advisory votes.
On Stock Titan, AIM ImmunoTech’s filings are updated as they appear on EDGAR, and AI-powered tools summarize key points from lengthy documents such as 10-Ks, 10-Qs, 8-Ks and proxy statements. This helps users quickly identify information on topics such as financial performance trends, exchange compliance, governance decisions and material agreements, while still allowing access to the full original filings for detailed review. Form 4 insider transaction data, when filed, can also be monitored alongside these core disclosures to give a fuller picture of corporate activity.
AIM ImmunoTech Inc. reports on an extensive R&D pipeline centered on its dsRNA drug Ampligen for late-stage pancreatic cancer, other solid tumors, antivirals, ME/CFS and post-COVID conditions, plus legacy product Alferon N Injection. The company highlights promising early- and mid-stage clinical data, orphan drug designations and multiple patents supporting oncology and antiviral strategies.
At the same time, AIM discloses recurring operating losses, net cash use, a working capital deficit and a stockholders’ deficit of approximately $9,783,000 as of December 31, 2025, leading management to conclude that substantial doubt exists about its ability to continue as a going concern. AIM is also not in compliance with NYSE American stockholders’ equity requirements and faces a potential delisting if it cannot raise equity above $6,000,000 by June 11, 2026, despite having regained compliance with minimum price rules via a 1‑for‑100 reverse split in 2025.
Mitigating steps include a third‑quarter 2025 vendor settlement that forgave $3,041,000 of legal fees in exchange for $1,875,000 of payments, recorded as other income, and a January 2026 stock dividend that reset Class E and F warrant terms, reduced their exercise price to $1.439 and allowed those warrants to be reclassified from liabilities to equity, which AIM states will significantly increase stockholders’ equity. The company also signed an agreement with Thermo Fisher Scientific’s PPD clinical research business to design an anticipated Phase 3 trial of Ampligen in late‑stage pancreatic cancer, reflecting its strategic focus on this indication as its most attractive commercial opportunity.
AIM ImmunoTech Inc. CEO and President Thomas K. Equels converted 25 shares of Series G Convertible Preferred Stock into 25,000 shares of common stock. The preferred stock position was reduced to zero, and his directly held common stock increased to 63,922 shares following the transaction.
AIM ImmunoTech Inc. director David I. Chemerow converted preferred stock into common shares. He converted 25 shares of Series G Convertible Preferred Stock into 25,000 shares of common stock through a derivative conversion at no stated cash price. A footnote explains each preferred share is convertible into 1,000 common shares, effectively valuing the conversion at $1.00 per common share. Following the conversion, he directly holds 28,441 shares of AIM ImmunoTech common stock, with no remaining Series G preferred shares reported.
AIM ImmunoTech director David I. Chemerow reported new derivative holdings tied to a rights offering. He now holds 25 shares of Series G Convertible Preferred Stock, each with a stated value of $1,000 and convertible into 1,000 shares of common stock, issued through a subscription right in a rights offering.
He also reported 50,000 Class G Warrants, each exercisable for one share of common stock at an exercise price of $1.00, likewise issued as part of a subscription right in a rights offering. Following these transactions, he directly holds 3,441 shares of common stock, alongside the preferred shares and warrants.
AIM ImmunoTech Inc. completed a previously announced rights offering, raising approximately $1.8 million by selling 1,842 units. Each unit included one share of Series G Convertible Preferred Stock and Class G warrants.
The company created a new Series G preferred series of 12,000 shares, each with a stated value of $1,000 and initially convertible into common stock at $1.00 per share, subject to standard anti-dilution adjustments. Conversions are limited so that holders generally cannot exceed 4.99% beneficial ownership, adjustable by the holder up to 9.99%. The rights offering also issued 3,684,000 Class G warrants, each exercisable for one share of common stock at $1.00 per share for five years. The Series G preferred is non-voting (with limited exceptions), participates with common stock in dividends and liquidation on an as-converted basis, and has no mandatory redemption features.
ImmunoTech Inc. filed Amendment No. 3 to its Form S-1 registration statement as an exhibits-only update, amending Item 16(a) in Part II while leaving the remainder of the registration statement unchanged.
The amendment provides a detailed estimate of issuance and distribution expenses totaling $272,262, including an SEC registration fee of $4,971.60, a FINRA filing fee of $5,900.00, and legal, accounting, agent and miscellaneous fees. It also restates Delaware law-based indemnification provisions for directors and officers, summarizes prior unregistered securities issuances to executives and directors under Section 4(a)(2) and Rule 701, lists extensive material contracts and corporate documents as exhibits, and includes standard Securities Act undertakings and signature blocks.
ImmunoTech Inc. filed a current report describing new investor and clinical update materials. The company furnished a February 2026 corporate presentation, a DURIPANC year-end interim clinical progress update, and a February 5, 2026 press release as exhibits, noting these are furnished rather than filed for liability purposes.
The update relates to an ongoing Phase I/II open-label study combining durvalumab (Imfinzi) and rintatolimod (Ampligen) in pancreatic cancer patients with stable disease after FOLFIRINOX therapy. ImmunoTech emphasizes that Ampligen is still under evaluation across several diseases and that significant additional testing and human trials are required, with no assurance of successful or favorable outcomes.
ImmunoTech Inc. is launching a rights offering registering subscription rights to purchase up to 12,000 Units, each with one Series G Convertible Preferred share, plus securities convertible into up to 9,996,000 common shares and exercisable for up to 19,992,000 additional common shares.
Each Unit is offered at a $1,000 subscription price, with one non-transferable right per common share (including shares underlying participating options and warrants) held as of February 10, 2026, and an over-subscription privilege. The offer is best-efforts, with no minimum proceeds and an expected net raise of about $10.65 million if fully subscribed.
The company plans to use proceeds for general corporate purposes, clinical and manufacturing costs for prospective Phase 2/3 pancreatic cancer trials, and repayment of certain debt. The offering also supports efforts to regain NYSE American equity compliance while advancing Ampligen-based oncology, antiviral, ME/CFS and post-COVID programs.
ImmunoTech Inc. is conducting a rights offering of 12,000 Units at $1,000 per Unit, each Unit consisting of one share of Series G Convertible Preferred Stock and 1,492 warrants. The preferred shares are convertible into up to 8,952,000 shares of common stock, and the warrants are exercisable for up to 17,904,000 additional common shares at $1.34 per share for five years.
Existing common stockholders and holders of specified options and warrants as of 5:00 p.m. Eastern on February 4, 2026 receive one non-transferable subscription right per share, with a basic right to buy one Unit and an over-subscription privilege, subject to proration and a 19.99% ownership cap. The rights expire at 5:00 p.m. Eastern on February 23, 2026, and the offering is on a best-efforts basis with no minimum.
Assuming full subscription, ImmunoTech expects net proceeds of about $10.65 million, excluding any warrant exercises, and could receive an additional $23.99 million if all warrants are later exercised for cash. The company plans to use proceeds for general corporate purposes, including clinical and manufacturing costs for pancreatic cancer trials, and to repay certain existing debt, while highlighting significant dilution, liquidity and NYSE American listing risks.
AIM ImmunoTech Inc. filed a current report describing that it has furnished to warrant holders two notices dated January 20, 2026, detailing changes and modifications to its Class E and Class F Common Stock Purchase Warrants. These notices, included as Exhibits 99.1 and 99.2, outline revised terms for those existing warrants but are provided for information purposes under Regulation FD and are not deemed filed under securities laws. The company also reiterates standard forward-looking statement cautions and emphasizes that further clinical testing is required to determine the effectiveness of its product candidate Ampligen® across various conditions.